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ABSTRACT 
Tobacco consumption has become a major public health issue, which has motivated studies to identify and under-
stand the biological processes involved in the smoking behavior for prevention and smoking cessation treatments. 
CYP2A6 has been identified as the main gene that codifies the enzyme that metabolizes nicotine. Many alleles 
have been identified after the discovery of CYP2A6, suggesting a wide interethnic variability and a diverse smok-
ing behavior of the allele carrying individuals. The main purpose of this review is to update and highlight the 
effects of the CYP2A6 gene variability related to tobacco consumption reported from diverse human populations. 
The review further aims to consider CYP2A6 in future studies as a possible genetic marker for the prevention and 
treatment of nicotine addiction. Therefore, we analyzed several population studies and their importance at address-
ing and characterizing a population using specific parameters. Our efforts may contribute to a personalized system 
for detecting, preventing and treating populations at a higher risk of smoking to avoid diseases related to tobacco 
consumption. 
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INTRODUCTION 
Tobacco consumption has become an ep-
idemic affecting more than 1,000 million peo-
ple worldwide and is considered the main 
cause of avoidable death causing approxi-
mately 6 million premature deaths each year 
(WHO, 2011). Thus, tobacco consumption is 
a public health issue combined with economic 
losses; it has motivated studies for identifying 
and understanding the biological processes 
involved in the smoking behavior for preven-
tion and smoking cessation treatments (Bierut 
et al, 2014). 
Among cigarette compounds, nicotine is 
responsible for causing dependence by stimu-
lating the smoker and allowing the other com-
pounds to access the body, causing chronic 
harmful effects and tobacco-related diseases. 
Tobacco consumption is caused by envi-
ronmental, psychosocial and genetic factors 
(Bierut, et al., 2014). Previous studies have 
identified genes encoding proteins that influ-
ence nicotine addictive behavior due to their 
effect on the cerebral neurotransmission path-
ways (Al Koudsi and Tyndale, 2005; Arinami 
et al., 2000; Verde Rello and Santiago 
Dorrego, 2013). Moreover, some gene prod-
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ucts are involved in nicotine response as re-
ceptors and metabolizers (Hukkanen et al., 
2005; Verde Rello and Santiago Dorrego, 
2013). Pérez-Rubio et al. (2015) have re-
viewed this subject in detail. In the metaboliz-
ers group, the CYP2A6 gene plays an im-
portant role. Its protein product (by the same 
name) is the principal enzyme responsible for 
nicotine metabolism to cotinine and other 
sub-products in the human body. However, 
more than 45 alleles have been discovered 
suggesting wide interindividual and inter-
ethnic variety. 
The main purpose of this review is to up-
date and highlight the effects of the genetic 
polymorphisms of CYP2A6 related to tobacco 
consumption reported in diverse human pop-
ulations. Moreover, we aimed to consider 
these polymorphisms in future studies as pos-
sible genetic markers for the prevention and 
treatment of nicotine addiction. 
 
BIOLOGICAL FUNCTION OF CYP2A6 
IN SMOKING 
The CYP2A6 enzyme belongs to the en-
zyme superfamily known as the cytochrome 
P450 system (CYP450), also classified in the 
drug metabolizing enzymes group. These en-
zymes are found in the endoplasmic reticulum 
of the cells of some tissues in the body, par-
ticularly in the liver. Moreover, they are phase 
I enzymes responsible for metabolizing more 
than 80 % of drugs such as xenobiotics and 
endogen products in the body (Evans and 
Relling, 2004; Ingelman-Sundberg, 2004). 
CYP2A6 is found mainly in the liver and 
is approximately 5-10 % of the total CYP450 
content (Shimada et al., 1996; Yamano et al., 
1990), although it has also been found to be 
expressed in the nasal mucosa, trachea, bron-
chi, lungs, sinuses and several brain regions 
(Bhagwat et al., 2000; Chiang et al., 2012; 
Crawford et al., 1998; Ding and Kaminsky, 
2003; Macé et al., 1998). 
CYP2A6 has demonstrated to be involved 
in the metabolism of some endogen and ex-
ogen substrates such as precarcinogenic and 
carcinogenic compounds, as well as some 
toxins and drugs including nicotine. 
CYP2A6 has been particularly important 
in tobacco consumption because of its in-
volvement in nicotine metabolism. Nicotine is 
the main compound in tobacco responsible for 
the development of cigarette addiction by 
stimulating nicotinic cholinergic receptors 
(nAChR) that release neurotransmitters in the 
brain and cause a pleasant sensation in the 
smoker. The nicotine availability in the body 
is mediated by biological factors, mainly 
those related to its metabolism. Smokers tend 
to consume the same amount of nicotine each 
day to acquire the desired effects by modulat-
ing their smoking behavior to adjust nicotine 
availability for the purpose of regulating nic-
otine levels in the body (Benowitz, 1992). 
It has been reported that CYP2A6 is the 
main enzyme involved in the nicotine oxida-
tion to cotinine. CYP2A6 catalyzes approxi-
mately 80 % (55-92 %) of this reaction via C-
oxidation in addition to other metabolic path-
ways for nicotine and its metabolites 
(Benowitz and Jacob III, 1994; Messina et al., 
1997; Nakajima et al., 1996). Some other en-
zymes of CYP450 contribute to a lesser de-
gree to nicotine metabolism such as CYP2B6, 
CYP2A13, CYP2D6 and CYP2E1 (men-
tioned in the order of relevance). 
These biological products interact directly 
with nicotine to affect physiological brain 
processes (e.g., nAChR) and are inactivated 
and removed from the body (e.g., CYP450 en-
zymes) making their genes ideal candidates 
for altering smoking behavior (Malaiyandi et 
al., 2005). 
 
CYP2A6 GENETIC VARIANTS 
The CYP2A6 gene has a 6 kb extension 
length, and it is composed of 9 exons, which 
encode for a 494 amino-acid product 
(Fernandez-Salguero et al., 1995). It is lo-
cated in the chromosomal band 19q13.2, 
where other CYP450 gene subfamilies 
(CYP2B, CYP2F, CYP2G, CYP2S, and 
CYP2T) are also present. The CYP2A sub-
family cluster includes the CYP2A6, CYP2A7, 
and CYP2A13 genes and other pseudogenes 
(Hoffman et al., 2001). 
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The Human CYP-Allele Nomenclature 
Database (HCAND) (http://www.cypal-
leles.ki.se) was created in 1999 for the identi-
fication and characterization of CYP2A6 al-
leles (and other CYP450 genes). This data-
base consists of a committee for unifying and 
assigning nomenclature for the already dis-
covered alleles and alleles to be discovered in 
the future (Sim and Ingelman-Sundberg, 
2010, 2013).  
To date, 42 well-characterized alleles and 
some haplotypes that are uncharacterized 
(“CYP2A6 allele nomenclature,” 2014) have 
been identified. These alleles are determined 
according to the origins of their mutation(s), 
such as gene conversion, gene deletion, gene 
duplication and/or single nucleotide polymor-
phism (SNP). The gene mutations are summa-
rized in Figure 1. 
The wild-type allele that is considered as 
a reference is CYP2A6*1A (Yamano et al., 
1990). CYP2A6*1B consists of a 58 bp gene 
conversion with CYP2A7 in the CYP2A6 3’ 
UTR region (Ariyoshi et al., 2000; Yamano et 
al., 1990). In vitro and in vivo assays have 
shown that the CYP2A6 3’ UTR region has 
more enzymatic activity and RNA stabiliza-
tion than the reference allele (Ho et al., 2009; 
Wang et al, 2006; Yoshida et al., 2002). How-
ever, several haplotypes contain this gene 
conversion and other noncoding genetic 
changes and have been designated 
CYP2A6*1B1-B17 (Ariyoshi et al., 2000; 
Haberl et al., 2005; Mwenifumbo et al., 2007, 
2008, 2010; Nakajima et al., 2006; Pitarque et 
al., 2004; Yamano et al., 1990). Moreover, it 
has been determined that other wild-type al-
leles, named CYP2A6*1D-L, that have ge-
netic changes in coding, noncoding and regu-
latory regions (Mwenifumbo et al., 2008, 
2010; Nakajima et al, 2004; Pitarque et al., 
2004; von Richter et al., 2004; Yamano et al., 
1990). 
CYP2A6*2 consists of a missense muta-
tion of 1799T>A, causing an amino acid 
change of Leu160His in the enzyme. Thus, 
the protein does not incorporate the heme 
group, inactivating the enzyme for in vitro 
and in vivo assays (Benowitz et al., 1995; 
Hadidi et al., 1997; Oscarson, et al., 1999b; 
Yamano et al., 1990). 
CYP2A6*3 is presumed to be a gene con-
version of CYP2A6 to CYP2A7, which results 
in an inactive enzyme; however, the method-
ology for their detection, function, and allelic 
frequency has been controversial (Fernandez-
Salguero et al., 1995; Oscarson et al., 1998; 
Yamano et al., 1990). 
 
 
Figure 1: CYP2A6 location and mutations in the gene. Mutations are reported by the Human CYP-Allele 
Nomenclature Database (http://www.cypalleles.ki.se) and include insertion, deletion, CNV and SNP. Ref 
Seq NG_008377.1 
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CYP2A6*4 consists of a homologous un-
equal crossover with CYP2A7 on several po-
sitions (CYP2A6*4A-F), which leads to a 
whole gene deletion causing loss of enzy-
matic activity (Kitagawa et al., 1999; 
Nakajima et al., 2000, 2001; Nunoya et al., 
1999). 
CYP2A6*5 contains a missense mutation, 
6582G>T, creating a Gly479Val amino acid 
change and resulting in a lack of enzyme 
function (Oscarson et al., 1999b). 
CYP2A6*6 contains a missense mutation, 
6582G>T, which creates an Arg128Gln 
amino acid change causing lower enzymatic 
activity of the enzyme (Kitagawa et al., 2001). 
CYP2A6*7 contains a missense mutation, 
6558G>A, which produces an Ile471Thr 
amino acid change that decreases the enzy-
matic activity to metabolize some substrates 
for in vivo and in vitro assays (Ariyoshi et al, 
2001; Uno et al., 2013; Xu et al., 2002). 
CYP2A6*8 contains a missense mutation, 
6600G>T, creating an amino acid change in 
Arg485Leu; however, the mutation’s effect 
apparently does not change the enzymatic ac-
tivity (Xu et al., 2002). 
CYP2A6*9 contains a point mutation,  
-48T>G, on the TATA box located in the gene 
promoter, which results in a decrease of more 
than 50 % of the enzymatic activity for in 
vitro and in vivo assays (Pitarque et al., 2001; 
Yoshida et al., 2003). There have been identi-
fied two subtypes of this allele: CYP2A6*9A, 
which contains an additional -1013A>G point 
mutation (von Richter et al., 2004), and 
CYP2A6*9B, which contains the point muta-
tions -1680A>G, -1301A>C, -1289G>A, 
1620T>C, 1836G>T, 6354T>C and 
6692C>G (Haberl et al., 2005). 
CYP2A6*10 contains two point muta-
tions, similar to the CYP2A6*7 and 
CYP2A6*8 alleles. These point mutations de-
crease the enzymatic activity dramatically 
and make it completely inactive for some sub-
strates (Xu et al., 2002). 
CYP2A6*11 contains a missense muta-
tion, 3391T>C, which results in the amino 
acid change of Ser224Pro, decreasing the en-
zymatic activity (Daigo et al., 2002). 
CYP2A6*12A originated by the unequal 
crossover between CYP2A6 and CYP2A7, 
which resulted in a hybrid allele at the 5’ UTR 
and exons 1- 2 belonging to CYP2A7 and 
from the 3rd to 9th exon belonging to CYP2A6. 
This generates a 10 amino acid substitution 
compared to the reference allele (Oscarson et 
al., 2002). Later, several SNPs were discov-
ered in the same allele, which generates two 
subvariants (CYP2A6*12B-C) (Haberl et al., 
2005). These alleles are classified as null en-
zymatic activity (Bloom et al., 2011). 
CYP2A6*13 has two point mutations: the 
first at -48T>G in the TATA box of the pro-
moter and the second at 13G>A changes the 
amino acid Gly5Arg. The enzymatic activity 
is decreased (Kiyotani et al., 2002; Nakajima 
et al., 2006). 
CYP2A6*14 has the missense mutation 
86G>A and changes the Ser29Asn amino acid 
chain; however, this does not affect the enzy-
matic activity (Kiyotani et al., 2002; 
Nakajima et al., 2006). 
CYP2A6*15 is the product of two point 
mutations: the first at -48T>G in the TATA 
box of the promoter and the second at 2134 
A>G, which results in an amino acid change 
of Lys194Glu (Kiyotani et al., 2002). How-
ever, this enzyme does not show differences 
in substrate metabolism (Tiong et al., 2014; 
2010). 
CYP2A6*16 has a missense mutation at 
2161C>A, which makes an amino acid 
change of Arg203Ser (Kiyotani et al., 2002); 
however, it does not cause a defect in the en-
zymatic activity (Ho et al., 2008; Nakajima et 
al., 2006; Tiong et al., 2014, 2010). 
CYP2A6*17 shows several point muta-
tions, 51G>A, 209C>T, 1779G>A, 4489C>T, 
5065G>A, 5163G>A, 5717C>T and 
5825A>G, which result in the amino acid 
change Val365Met and cause a decrease in 
the enzymatic activity of the allele (Fukami et 
al., 2004). 
CYP2A6*18 has three subvariants that 
share the missense mutation at 5886A>T and 
the amino-acid change Tyr392Phe. 
CYP2A6*18A only has that point mutation 
while CYP2A6*18B also has synonymous 
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substitutions at 51G>A, 5684T>C and 
5702T>C. CYP2A6*18C also has the point 
mutations at -1680A>G, -1579T>C,  
-1464A>T, -1301A>C, -1289G>A,  
-1013A>G, 1620T>C, 5668A>T and 
6692C>G. The enzymatic activity of this al-
lele tends to be specific according to the sub-
strate (Fukami et al., 2005a; Haberl et al., 
2005). 
CYP2A6*19 is produced by the point mu-
tations at 5668A>T, 6354T>C, and 6558T>C 
and a gene conversion at the 3’UTR with 
CYP2A7, which correspond to the amino acid 
changes of Tyr392Phe and Ile471Thr, de-
creasing the enzymatic activity (Fukami et al., 
2005a). 
CYP2A6*20 has a frameshift mutation at 
nucleotides 2140 and 2141, which displaces 
the frameshift from the codon 196 to stop 
prematurely at 220 codons. In addition, it has 
three point mutations at 51G>A, 5684T>C 
and 6692C>G. These mutations produce a 
loss-of-function enzyme (Fukami et al., 
2005b; Mwenifumbo et al., 2008). 
CYP2A6*21 is the result of two point mu-
tations: 51G>A and 6573A>G, which pro-
duce an amino acid change Lys476Arg 
(Haberl et al., 2005). However, the functional 
effect of the enzyme is still under discussion 
because it has been reported that in vivo as-
says show differences according to the study 
population (Al Koudsi et al., 2006; 
Mwenifumbo et al., 2008) and in vitro assays 
show normal enzymatic activity (Tiong et al., 
2014, 2010). 
CYP2A6*22 is the result of three point 
mutations: 51G>A, 1794C>G and 1798C>A, 
which cause the amino acid changes 
Asp158Glu and Leu160Ile (Haberl et al., 
2005). These mutations reduce the enzyme af-
finity to the substrates; CYP2A6*22 has 39 % 
of the enzyme activity compared to the refer-
ence allele (Tiong et al., 2014, 2010). 
CYP2A6*23 contains a point mutation at 
2161C>T that corresponds to the amino acid 
change Arg203Cys; this decreases the enzy-
matic activity to 19 % compared to the refer-
ence allele (Ho et al., 2009, 2008). 
CYP2A6*24 has two subvariants, among 
which CYP2A6*24A has the following point 
mutations: -1301A>C, -1289G>A,  
-1013A>G, 51G, 578A>G, 594G>C, 
720G>A, 1137C>G, 1620T>C, 2483G>A, 
3225A>G, 5668A, 6218A>G, 6282A>G, 
6293T>C, 6354T>C, 6458A>T, , 6782C>G 
and 7160A>G, as well as a gene conversion 
in the 3’UTR of 58 bp. However, 
CYP2A6*24B has a 1381_1382CT>TC sub-
stitution and 1481_1486delCTCTCT dele-
tion. These mutations cause the amino acid 
changes Val110Leu and Asn438Tyr, which 
encode a loss-of-function enzyme 
(Mwenifumbo et al., 2008). 
CYP2A6*25 is the result of several point 
mutations, some of them in 5’UTR: -
1301A>C, -1289G>A and -745A>G, also 
22C>T, 51G, 768A>T, 1620T>C, 1672T>C, 
2296C>T, 2483G>A, 2605G>A, 2921G>A, 
2994T>C, 4636A>C, 5668A, 6586T>C, 
6692C>G and 7160A>G that result in the 
amino acid change of Phe118Leu 
(Mwenifumbo et al., 2008), it has been shown 
that its enzymatic activity is decreased in 
some substrates (Ho et al., 2009; 
Mwenifumbo et al., 2008; Uno et al., 2013). 
CYP2A6*26 is produced by the following 
point mutations: -1301A>C, -1289G>A,  
-745A>G, 22C>T, 51G, 1165G>A, 
1620T>C, 1672T>C, 1703G>T, 1710C>T, 
1711T>G, 2296C>T, 2483G>A, 2994T>C, 
4071delA, 4636A>C, 5668A, 6115C>T, 
6586T>C, 6692C>G and 7160A>G which 
make amino acid changes in Phe118Leu, 
Arg128Leu and Ser131Ala (Mwenifumbo et 
al., 2008). The in vivo and in vitro assays have 
proven that the final product is a loss-of-func-
tion enzyme (Ho et al., 2009; Mwenifumbo et 
al., 2008). 
CYP2A6*27 has the following point mu-
tations: -1301A>C, -1289G>A, -745A>G, 
22C>T, 51G, 1620T>C, 1672T>C, 
2162_2163GC>A, 2296C>T, 2483G>A, 
2994T>C, 3872G>A, 4071delA, 4636A>C, 
5668A, 5857T>A, 6586T>C, 6692C>G and 
7160A>G, which makes the amino acid 
change Phe118Leu and also have a frameshift 
mutation, which displaces the frameshift to 
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stop prematurely at 5th exon (Mwenifumbo et 
al., 2008), resulting in a loss-of-function en-
zyme (Ho et al., 2009; Mwenifumbo et al., 
2008). 
CYP2A6*28 has two subvariants that 
share the following mutations: -1269T>C, 
51G>A, 656G>T, 1620T>C, 4681T>G, 
5668A, 5738C>T, 5745A>G, 5750G>C, 
6354T>C, 6361C>A and 7160A>G, as well 
as a gene conversion in the 3’UTR of 58 bp. 
However, CYP2A6*28A also carries the point 
mutations 6385G>T, 6389C>G, 6390T>C 
and 6782C>G, on the other hand 
CYP2A6*28B has additionally the following 
mutations: 1381_1382CT>TC, 6960_6961ins 
GAAAAG and 1481_1486delCTCTCT. 
These mutations cause the amino acid change 
of Asn418Asp and Glu419Asp, however, the 
enzymatic activity is the same as the reference 
allele (Mwenifumbo et al., 2008). 
According to the HCAND, CYP2A6*29, 
30, 32 and 33 alleles are now in evaluation 
phase (“CYP2A6 allele nomenclature,” 
2014). 
CYP2A6*31 has two subvariants which 
share the following mutations: -1289G>A,  
-1013A>G, -492_-470delCCCCTTCCTGA-
GACCCTTAACCCinsAATCCATATGTGG
A ATCTG, 16A>C, 51G, 1339C>G, 
1620T>C, 2721G>A, 2994T>C, 3255A>G, 
3315C>T, 5668A, 6692C>G and 7160A>G. 
However, CYP2A6*31A also has the point 
mutation of 7568C>T and CYP2A6*31B the 
mutations in -975T>C, 467C>T and 
4074delA that cause the amino acid change 
Met6Leu (Mwenifumbo et al., 2008), but the 
enzymatic activity has not been evaluated. 
CYP2A6*34 originated by the unequal 
crossover between CYP2A6 and CYP2A7, 
which resulted in a hybrid allele at the 5’UTR 
and exons 1- 4 belonging to CYP2A7 and 
from the 5th to 9th exon belonging to CYP2A6 
(di Iulio et al., 2009). The enzymatic activity 
has not yet been evaluated, however could be 
similar to CYP2A6*12 and it might be a loss-
of-function allele. 
CYP2A6*35 has two subvariants that 
share the following mutations: -1301A>C,  
-1289G>A, 1620T>C, 6458A>T, 6782C>G, 
7160A>G and a gene conversion at the 
3’UTR with CYP2A7. However, 
CYP2A6*35A also has the following point 
mutations: -1013A>G, 720G>A, 1137C>G, 
2483G>A, 3225A>G, 6218A>G, 6282A>G, 
6293T>C and 6354T>C; on the other hand, 
CYP2A6*35B has the following point muta-
tions: -745A>G, 22C>T, 4084delA, 
6835C>A and 6999T>C (Al Koudsi et al., 
2010). These mutations produce a protein that 
has the amino acid change Asn438Tyr which 
decrease the enzymatic activity according to 
in vitro and in vivo assays (Al Koudsi et al., 
2010). 
CYP2A6*36 has the following point mu-
tations: -1301A>C, -1289G>A, -745A>G, 
22C>T, 1620T>C, 4084delA, 6458A>T, 
6558T>C, gene conversion at 3’UTR, 
6782C>G, 6835C>A, 6999T>C and 
7160A>G that change the amino acid of 
Asn438Tyr and Ile471Thr (Al Koudsi et al., 
2010). To date there are no assays that prove 
their enzymatic activity. 
CYP2A6*37 is produced by the following 
mutations: -1301A>C, -1289G>A, -745A>G, 
22C>T, 1620T>C, 4084delA, 6354T>C, 
6458A>T, 6558T>C, 6600G>T, 6782C>G, 
6835C>A, 6936_6937insCACTT, 
6961_6962insGAAAAG, 6989A>G, 
6999T>C, 7160A>G and a gene conversion at 
the 3’UTR, which make the amino acid 
changes Asn438Tyr, Ile471Thr and 
Arg485Leu (Al Koudsi et al., 2010). There 
are no assays that prove the enzymatic activ-
ity. 
CYP2A6*38 is a result of the missense 
mutation 5023A>G, which produces the 
amino acid change of Tyr351His (Bloom et 
al., 2011). An in silico assay classified the 
SNP as harmful, suggesting a decreased enzy-
matic activity (Bloom et al., 2011). 
CYP2A6*39 was described by Pilinguian 
et al. (2014) as a missense mutation of 
468G>A; however, the HCAND (“CYP2A6 
allele nomenclature,” 2014) adds the point 
mutations 171C>A, 1779G>A and 5717C>T, 
which cause the amino acid change 
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Val68Met. The enzymatic activity of this al-
lele is reported as decreased to half of the ref-
erence allele (Piliguian et al., 2014). 
CYP2A6*40 has the missense mutation 
1767C>G (Piliguian et al., 2014), but later the 
HCAND (“CYP2A6 allele nomenclature,” 
2014) added the point mutations 144G>A, 
3492C>T and 5738C>T, which modifies the 
amino acid to Ile149Met. The enzymatic ac-
tivity is reported to be half of the reference al-
lele (Piliguian et al., 2014). 
CYP2A6*41 contains the missense muta-
tion 3515G>A according to Pilinguian et al. 
(2014), but the HCAND (“CYP2A6 allele 
nomenclature,” 2014) added the point muta-
tions 51G>A and 507C>T, which changed the 
amino acid to Arg265Gln. This allele was 
shown to have a minimal alteration in expres-
sion and a normal enzymatic activity 
(Piliguian et al., 2014). 
CYP2A6*42 is the result of a missense 
mutation 3524T>C according to Pilinguian et 
al. (2014), but the HCAND (“CYP2A6 allele 
nomenclature,” 2014) added the mutations 
51G>A and 5684T>C, which made the amino 
acid change Ile268Thr that decreases the ex-
pression and enzymatic activity on in vivo and 
in vitro assays (Piliguian et al., 2014). 
CYP2A6*43 has the missense mutation 
4406C>T, which makes the amino acid 
change to Thr303Ile and shows decreased ex-
pression and enzymatic activity in in vivo and 
in vitro assays (Piliguian et al., 2014). 
CYP2A6*44 carries the missense muta-
tion 5661G>A according to Pilinguian et al. 
(2014), but later the HCAND (“CYP2A6 
allele nomenclature,” 2014) added the muta-
tions 51G>A, 5738C>T, 5745A>G and 
5750G>C, which modify the amino acids to 
Glu390Lys, Asn418Asp and Glu419Asp. 
These mutations have been shown to reduce 
the enzymatic activity and the reference allele 
expression to one-third (Piliguian et al., 
2014). 
CYP2A6*45 has a missense mutation at 
6531T>C according to Pilinguian et al. 
(2014), but later the HCAND (“CYP2A6 
allele nomenclature,” 2014) added the point 
mutations 51G>A and 4464G>A, which 
change the amino acid Leu462Pro. The muta-
tions have been proven (as in CYP2A6*44) to 
reduce the enzymatic activity and the refer-
ence allele expression to one-third (Piliguian 
et al., 2014). 
There are two CYP2A6 gene duplications: 
CYP2A6*1X2A originated by an unequal 
crossover from the 8th to 9th exon with 
CYP2A6*4D as a reciprocal product (Rao et 
al., 2000). CYP2A6*1X2B also originated by 
an unequal crossover of CYP2A7 from 5.2 to 
5.6 kb downstream of the stop codon with 
CYP2A6*4B as the reciprocal product 
(Fukami et al., 2007). Its enzyme activity has 
been shown to increase in in vivo assays (Rao 
et al., 2000). 
CYP2A6 has been suggested as a highly 
polymorphic gene because it is located in a 
small chromosomal region that contains sev-
eral genes and some unequal crossover 
events, point mutations and genetic conver-
sions between CYP2A6 and CYP2A7 
(Hoffman et al., 1995). These facts, plus evo-
lutionary forces such as genetic drift and nat-
ural selection, may have resulted in this ge-
netic variability, which spread among human 
populations (Ingelman-Sundberg, 2004, 
2005). This genetic variability, similar to 
other CYP450 genes, could explain the meta-
bolic response to exogenous compounds such 
as nicotine and other drugs that ranges from 
20-40 % (Ingelman-Sundberg, 2001). 
CYP2A6 genotypes can be classified ac-
cording to their alleles and their enzymatic ac-
tivity, which is referred to as the metabolism 
range of 3-hydroxycotinine/cotinine 
(Dempsey et al., 2004), as mentioned below: 
-Ultrarapid metabolizers. Individuals who 
have an enzymatic activity >100 % of normal; 
they contain more than two functional alleles 
(the CYP2A6*1X2 allele). 
-Normal metabolizers. Individuals who 
have an enzymatic activity of 100 % (nor-
mal); they contain two functional alleles. 
-Intermediate metabolizers. Individuals 
who have an enzymatic activity ≤75 % of nor-
mal may contain a functional and a defective 
allele or even two partially defective alleles. 
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-Slow metabolizers. Individuals who have 
an enzymatic activity ≤50 % of normal can 
contain a functional and a loss-of-function al-
lele or even two loss-of-function alleles. 
 
EFFECTS OF CYP2A6 GENETIC VARI-
ANTS ON TOBACCO CONSUMPTION 
The genetic variability of CYP2A6 di-
rectly influences the range of nicotine metab-
olism in the body, which can indirectly affect 
the reinforcing and aversive nicotine proper-
ties in the brain and can change the individual 
risk of nicotine dependence. To prove the ef-
fect of CYP2A6 variants on tobacco consump-
tion, several studies were conducted that in-
cluded family, twin and non-related subject 
designs. These studies associate an allele with 
the amount of metabolized nicotine or another 
variable related to tobacco consumption. 
Smokers who carry some CYP2A6 alleles 
show a different smoking behavior compared 
to carrying the wild-type allele, suggesting 
that smokers regulate their smoking behavior 
to obtain the desired nicotine levels in their 
body (Malaiyandi et al., 2005; Rao et al., 
2000; Schoedel et al., 2004). 
The importance of the null and decreased 
biological function alleles is explained in 
smokers (carrying these alleles) who exhibit 
less time smoking (Liu et al., 2011; 
Malaiyandi et al., 2006b), fewer cigarettes 
smoked (Audrain-McGovern et al., 2007; 
Fujieda et al., 2004; Malaiyandi et al., 2005; 
Minematsu et al., 2006; O’Loughlin et al., 
2004; Pan et al., 2015; Rao et al., 2000; 
Schoedel et al., 2004; Thorgeirsson et al., 
2010), fewer aspirations per cigarette 
(Strasser et al., 2011), later smoking onset 
(Gu et al., 2000; O’Loughlin et al., 2004; 
Schoedel et al., 2004) and less nicotine de-
pendence (Wassenaar et al., 2011). Likewise, 
it has been reported that these individuals re-
spond better to replacement nicotine therapy 
(Lerman et al., 2010; Malaiyandi et al., 
2006b). Moreover, they tolerate withdrawal 
symptoms (Kubota et al., 2006) better and 
have higher rates of quitting smoking sponta-
neously (Chenoweth et al., 2013; Malaiyandi 
et al., 2006b; Minematsu et al., 2003; Ray et 
al., 2009). These alleles have also been asso-
ciated with lung, bladder, nasopharyngeal, 
esophageal and oral cancer (Fujieda et al., 
2004; Hosono et al., 2015; Islam et al., 2013; 
Ito et al., 2015; Kumondai et al., 2016; 
Lourembam et al., 2015; Miyamoto et al., 
1999; Song et al., 2009; Tamaki et al., 2011; 
Tan et al., 2001; Tiwawech et al., 2006; 
Topcu et al., 2002; Wassenaar et al., 2015). 
On the other hand, some reports do not 
prove the association between null and de-
creased CYP2A6 alleles related to tobacco 
consumption (London et al., 1999; Loriot et 
al., 2001; Sabol and Hamer, 1999; Schulz et 
al., 2001; Tiihonen et al., 2000; Zhang et al., 
2001). This lack of association may occur be-
cause of several factors such as designing the 
population stratification (comparing popula-
tions where there are substructures between 
cases and controls) and population ethnicity, 
lack of detailed phenotypic evaluation, inde-
terminate comorbidities, different genotyping 
methods, examination of different allelic var-
iants, inconsistency in smoking history and 
differences in symptoms of nicotine depend-
ence among smokers (Lerman and Niaura, 
2002; O’Loughlin et al., 2004). 
Detecting the alleles of CYP2A6 can allow 
us to characterize different smoking behav-
iors and smoking-related diseases among in-
dividuals (Fujieda et al., 2004), due to their 
role in nicotine metabolism and the metabo-
lism of certain carcinogenic compounds. This 
could have an implication on public health by 
reducing the harmful effects related to smok-
ing and developing a personalized smoking 
cessation according to their individual geno-
type (Liu et al., 2011; Schoedel et al., 2004). 
However, these alleles have a specific distri-
bution in worldwide populations. 
 
POPULATION DISTRIBUTION OF 
CYP2A6 ALLELES 
The CYP2A6 allele distribution has an 
interethnic pattern. Knowing the individual 
differences in nicotine metabolism may allow 
us to answer the following questions: Why do 
some people become regular smokers after in-
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itial exposure, while others experience nega-
tive reactions and discontinue use? Why do 
some people smoke in greater quantities than 
others? Why do different individuals not re-
spond the same way to drug therapies to quit 
smoking? Why do some individuals develop 
smoking related diseases faster than others? 
(O’Loughlin et al., 2004; Schoedel et al., 
2004; Swan et al, 1997, 2005). 
Therefore, we present the allele frequen-
cies in reported populations where tobacco 
consumption, cancer and nicotine metabolism 
were studied and in cohorts and general pop-
ulation studies, which involve CYP2A6. The 
number of reports of each allele according to 
a population group is summarized in Figure 2. 
For more practical reasons, we only showed 
the frequency without distinction for alleles 
with subvariants, except for the wild-type al-
lele CYP2A6*1 whose frequency was not 
completely calculated because some studies 
assign an unidentified genotype to the refer-
ence allele. 
The wild-type allele subvariants are dis-
tributed in a particular way on worldwide 
populations. CYP2A6*1A is found in almost 
all populations studied such as Caucasian 
populations (Spanish, British, French, Swe-
dish and Serbian), which range from 57-67 % 
(Djordjevic et al., 2010, 2013; Gambier et al., 
2005; Huang et al., 2005; Nakajima et al., 
2006, 2004; Oscarson, et al., 1999a; Soriano 
et al., 2011), Africans, and Ethiopians, which 
reported an allele frequency of 34.8 % 
(Aklillu et al., 2014). However, in African 
Americans, Ghanaians and Namibians the fre-
quencies were between 66.5-80.5 % (Gyamfi 
et al., 2005; Nakajima et al., 2004; Takeshita 
et al., 2006) while it was the opposite in 
Asians. Asians living in the UK report a fre-
quency of 64.1 % while East and South Asian 
populations (Chinese, Japanese, Korean, Ma-
laysian, Thai, Indian, Bangladeshi and Sri 
Lankan) report a frequency of 27-52 % 
(Ariyoshi et al., 2002; Djordjevic et al., 2013; 
Islam et al., 2013; Ito et al., 2015; Iwahashi et 
al., 2004; Kwon et al., 2001; Mahavorasirikul 
et al., 2009; Nakajima et al., 2001, 2006; 
Nurfadhlina et al., 2006; Oscarson et al., 
1999a; Peamkrasatam et al., 2006; Takeshita 
et al., 2006; Topcu et al., 2002; Yoshida et al., 
2002). In the Middle East, the Turkish report 
a frequency of 23.9-69.7 % (Takeshita et al., 
2006; von Richter et al. (2004). The American
 
 
Figure 2: CYP2A6 alleles reported in tobacco consumption related studies. Number of CYP2A6 alleles 
that have reported frequencies in population and association studies related to tobacco/nicotine con-
sumption and cancer related to tobacco consumption (in the population study).  
The populations are grouped according to possible ancestral and / or geographical origin: African (Canadian, American, Ghanaian, 
Ethiopian, Namibian, “African” and “Black” populations). Caucasian (German, Canadian, American, Spanish, Finish, French, Hun-
garian, English, Serbian, Swedish, “Caucasian” and “Whites”). East Asian (Chinese, Korean, Japanese, Malaysia, Thai, Taiwan-
ese, Vietnamese, Han Chinese, Uighur, Bouyei, Tibetan, Shimane, Tottori, Fukuoka, Ehime and “Asian”) South Asian (Indian, 
Bangladeshi, Sri Lanka, Tamilian, Kannadika, Keralites and Andhrites). Middle East (Iranian, Turkish, Tatar, Turks, Turkomans 
and Zoroastrian Persians). American Continent (Hispanic, Brazilian, Chilean, Ecuadorian, Mexican, Canadian Native and Alaskan 
Yupik). Oceania (Neo Zealander Māori). *Except African American, American and Canadian. 
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mestizo populations such as Brazilian and Ec-
uadorian show a frequency of 71.7 % (Rossini 
et al., 2006) and 61.7 % (Soriano et al., 2011), 
respectively. CYP2A6*1B frequency is higher 
in East and South Asian populations and is re-
ported as 26.7-54.2 % (Ariyoshi et al., 2002; 
Djordjevic et al., 2013; Islam et al., 2013; Ito 
et al., 2015; Iwahashi et al., 2004; Kwon et al., 
2001; Lourembam et al., 2015; 
Mahavorasirikul et al., 2009; Nakajima et al., 
2001, 2006; Nurfadhlina et al., 2006; 
Oscarson et al., 1999a; Peamkrasatam et al., 
2006; Schoedel et al., 2004; Takeshita et al., 
2006; Tiwawech et al., 2006; Topcu et al., 
2002; Yoshida et al., 2002; Yusof and Gan, 
2009). In Caucasians (Nonspecific, North 
American, Spanish, British, French, Swedish 
and Serbian) a frequency of 27.6-33.5 % 
(Bloom et al., 2011; Djordjevic et al., 2013, 
2010; Gambier et al., 2005; Haberl et al., 
2005; Huang et al., 2005; Nakajima et al., 
2006, 2004; Oscarson et al., 1999a; Schoedel 
et al., 2004; Soriano et al., 2011) is reported, 
but it is lower in Turkish populations (25.9-
26.7 % (Takeshita et al., 2006; von Richter et 
al., 2004)). African populations such as Afri-
can American, Ghanaian and Namibian show 
lower frequencies (11.2-19.8 % (Gyamfi et 
al., 2005; Ho et al., 2009; Mwenifumbo et al., 
2008; Nakajima et al., 2006, 2004; Schoedel 
et al., 2004; Takeshita et al., 2006)), except 
for Ethiopian populations (31.3 % (Aklillu et 
al., 2014)). American mestizo populations 
(Brazilian and Ecuadorian) have a frequency 
of 26.4-31.2 % (Rossini et al., 2006; Soriano 
et al., 2011; Vasconcelos et al., 2005) while 
the Native Canadian and Alaskan Yupik show 
a frequency of 55-65.3 % (Rossini et al., 
2006; Soriano et al., 2011; Vasconcelos et al., 
2005). CYP2A6*1D showed a higher fre-
quency in the African nonspecific population 
(>50 % (Nakajima et al., 2006)) than in the 
Ethiopian population (29.4 %) (Aklillu et al., 
2014). In the Caucasian population (Nonspe-
cific, North American and Swedish) the fre-
quency is 26.7-40 % (Bloom et al., 2011; 
Nakajima et al., 2006; von Richter et al., 
2004) and in Turkish populations it is 32.3 % 
(von Richter et al., 2004). Asian populations 
(Japanese and Korean) show a frequency of 
10-20 % (Nakajima et al., 2006). CYP2A6*1F 
has been reported only in nonspecific Cauca-
sian (1.8 % (Nakajima et al., 2004)) and Turk-
ish (2.2 % (Takeshita et al., 2006)) popula-
tions, but was not found in African and Japa-
nese populations (Nakajima et al., 2004; 
Takeshita et al., 2006). CYP2A6*1G has a 
higher frequency in African populations 
(North American and Namibian) (12.3-
13.3 % (Nakajima et al., 2004; Takeshita et 
al., 2006)) than in Caucasian populations 
(1.2 % (Nakajima et al., 2004)), but it was not 
reported in Turkish and Japanese populations 
(Takeshita et al., 2006). CYP2A6*1H has 
been found higher in Caucasian populations 
such as nonspecific Caucasian (>11 % 
(Nakajima et al., 2006)), North American 
(7.9 % (Bloom et al., 2011)) and Swedish 
(3.1 % (von Richter et al., 2004)), followed by 
nonspecific African (9.8 % (Nakajima et al., 
2006)), Turkish (5.2 % (von Richter et al., 
2004)), Japanese (4.5 % (Nakajima et al., 
2006)) and Korean (1.6 % (Nakajima et al., 
2006)). CYP2A6*1J has been reported as non-
existent in Caucasian, African, Japanese and 
Korean populations (Nakajima et al., 2006). 
CYP2A6*2 has a higher frequency in Cau-
casian populations such as nonspecific Cau-
casian (1.1-5.3 % (Audrain-McGovern et al., 
2007; Benowitz et al., 2006; Haberl et al., 
2005; Malaiyandi et al., 2006a, b; Nakajima 
et al., 2006, 2004; Paschke et al., 2001; Rao 
et al., 2000; Schoedel et al., 2004; Xu et al., 
2002)), English populations such as British 
(2.5 % (Huang et al., 2005)) and Canadian 
(3.4 % (O’Loughlin et al., 2004)); and in Cen-
tral Europe populations such as German, 
French and Spanish it has been reported from 
2.3-3 % (Bourian et al., 2000; Loriot et al., 
2001; Oscarson, et al., 1999b)). In North of 
Europe populations such as Finish and Swe-
dish, a frequency of 1.1-3 % (Oscarson et al., 
1998, 1999b) was reported. In African popu-
lations (Afro American and Ethiopian), the 
frequency is less than 1 % (Malaiyandi et al., 
2005; Nakajima et al., 2006; Schoedel et al., 
2004) and is not reported in Ghanaian popu-
lations (Gyamfi et al., 2005). The frequency 
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is different in American populations: Amerin-
dian populations, Canadian natives and Alas-
kan Yupik have a frequency less than 1 % 
(Binnington et al., 2012; Nowak et al., 1998; 
Schoedel et al., 2004). However, the mestizo 
populations such as Brazilian (1.6-1.7 %) 
(Rossini et al., 2006; Vasconcelos et al., 
2005) and Chilean (2-3.7 %) (Cáceres et al., 
2012; Roco et al., 2012) show a frequency 
higher than Hispanics (Benowitz et al., 2006). 
In East and Southeast Asian populations such 
as Chinese, Korean, Japanese, Malaysian and 
Thai, CYP2A6*2 is non-existent (Huang et 
al., 2005; Kitagawa et al., 1999; Malaiyandi 
et al., 2005; Nakajima et al., 2006; 
Nurfadhlina et al., 2006; Oscarson et al., 
1999b; Schoedel et al., 2004). A minimum 
range of 1 % (Nurfadhlina et al., 2006) was 
reported in Indians. The Iranian population 
had a frequency higher than 2.2 % 
(Emamghoreishi et al., 2008; Heravi et al., 
2010), unlike the Turkish population where 
CYP2A6*2 was not found (Cok et al., 2001). 
The methodologies for the detection, 
function and allelic frequency of CYP2A6*3 
have been controversial (Fernandez-Salguero 
et al., 1995; Oscarson et al., 1998; Yamano et 
al., 1990); however, we present the reported 
frequency. The highest frequency (13.8 % 
(Nowak et al., 1998)) was reported in Cana-
dian natives, followed by Turkish (12 % (Cok 
et al., 2001)), German (1.4 %) (Bourian et al., 
2000) and Indian (1.1 %) (Nurfadhlina et al., 
2006) populations. However, in African 
(Nakajima et al., 2006; Paschke et al., 2001). 
Caucasian (Nakajima et al., 2006; Paschke et 
al., 2001), Spanish (Oscarson et al., 1999a), 
Chilean (Cáceres et al., 2012), Iranian (Heravi 
et al., 2010), Korean (Kwon et al., 2001; 
Nakajima et al., 2006; Yoshida et al., 2002), 
Chinese (Nurfadhlina et al., 2006; Oscarson et 
al., 1999b), Malaysian (Nurfadhlina et al., 
2006) and Japanese (Nakajima et al., 2001, 
2006; Yoshida et al., 2002) (except a report of 
0.2 % (Minematsu et al., 2003)) populations, 
this allele was not found.  
CYP2A6*4 may be the most widely stud-
ied allele in all populations. East Asian popu-
lations such as Japanese (11.2-25.6 % 
(Ariyoshi et al., 2002; Fujieda et al., 2004; 
Fukami et al., 2006; Ito et al., 2015; Iwahashi 
et al., 2004; Minematsu et al., 2003, 2006; 
Nakajima et al., 2001, 2006; Schoedel et al., 
2004; Takeshita et al., 2006; Tamaki et al., 
2011; Xu et al., 2002; Yoshida et al., 2002)), 
Chinese (4.9-14 % (Gu et al, 2005; Liu et al., 
2011; Nurfadhlina et al., 2006; Oscarson et 
al., 1999a; Schoedel et al., 2004; Song et al., 
2009; Tan et al., 2001; Xu et al., 2002; Yuan 
et al., 2016)), Korean (9.4-11 %) (Djordjevic 
et al., 2013; Fukami et al., 2006; Kwon et al., 
2001; Nakajima et al., 2006; Yoshida et al., 
2002), Thai (4-14.2 % (Mahavorasirikul et 
al., 2009; Peamkrasatam et al., 2006; 
Tiwawech et al., 2006)), Malaysian (7-16.7 % 
(Nurfadhlina et al., 2006; Yusof and Gan, 
2009)) and Vietnamese (11.8 % (Veiga et al., 
2009)) showed the highest frequency among 
populations. However, some Asian popula-
tions that reside in a foreign country such as 
those living in the UK report a frequency of 
less than 1 % (Benowitz et al., 2006; Huang 
et al., 2005). However, ethnic populations in 
Asian countries show no differences in the 
frequencies such as in Japan with the Shimane 
(18.2 %), Tottori (16.9 %), Fukoka (20.6 %) 
and Ehime (25.9 % (Takeshita et al., 2006) 
and in China with the Han (7.9 %), Uighur 
(15 %), Bouyei (0 %) and Tibetan (2 %) 
(Pang et al., 2015). South Asian populations 
such as Bangladeshi (4.7-11.2 % (Islam et al., 
2013)), Sri Lankan (2.8-9.6 % (Topcu et al., 
2002)) and Indian (1.5-8.9 % (Krishnakumar 
et al., 2012; Nurfadhlina et al., 2006) show a 
high frequency. Middle East populations such 
as Turkish (2.2 % (Takeshita et al., 2006)) 
and Iranian (0.9-2.5 % (Emamghoreishi et al., 
2008; Heravi et al., 2010)) show a lower fre-
quency. However, the distribution is different 
in Caucasian populations: Nonspecific Cau-
casians had a frequency lower than 3 % 
(Audrain-McGovern et al., 2007; Benowitz et 
al., 2006; Fukami et al., 2006; Malaiyandi et 
al., 2006a, b; Nakajima et al., 2006, 2004; Rao 
et al., 2000; Schoedel et al., 2004; Xu et al., 
2002); Atlantic Europe populations such as 
Spanish (0.5-4 % (Oscarson et al., 1999b; 
Soriano et al., 2011)) and French (3.8 % 
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(Gambier et al., 2005)) also have this allele; 
English populations such as British (0.3 % 
(Huang et al., 2005)), North American (1.6 % 
(Bloom et al., 2011)) and Canadian (0.2 % 
(O’Loughlin et al., 2004)) had a lower fre-
quency; North of Europe populations such as 
Finish (1 % (Oscarson et al., 1999b)) and 
Swedish (1.1 % (Djordjevic et al., 2013)) also 
report this allele. Southeastern Europe popu-
lations such as Serbian report a frequency of 
2.9 % (Djordjevic et al., 2010) and Tatar from 
Russia reported a frequency range from 6.8-
16.9 % (Korytina et al., 2014). African popu-
lations had a frequency less than 2 % and are 
reported as follows: Nonspecific African 
(≤1.9 % (Ho et al., 2009; Nakajima et al., 
2006; Schoedel et al., 2004)), African Ameri-
can (0.5-0.6 % (Fukami et al., 2006; 
Nakajima et al., 2004)), Ghanaian (2 % 
(Gyamfi et al., 2005)), Ethiopian (0.6 % 
(Aklillu et al., 2014)) and Namibian (0 % 
(Takeshita et al., 2006)). American popula-
tions show a variable frequency: Amerindian 
populations as Alaskan Yupik (14.5 % 
(Binnington et al., 2012)) have a higher fre-
quency than Canadian natives (1 % (Schoedel 
et al., 2004)) and more than mestizo popula-
tions as Brazilian (0.5 % (Vasconcelos et al., 
2005)), Ecuadorian (7.1 % (Soriano et al., 
2011)), Chilean (3.7-4 % (Cáceres et al., 
2012; Roco et al., 2012)) and Hispanics (0 % 
(Benowitz et al., 2006)). On the other side of 
the world, the Māori native population from 
New Zealand report a high frequency (9.6 % 
(Lea et al., 2008)) of this allele and it is the 
only population reported in Oceania. 
CYP2A6*5 is found in a higher frequency 
in Asian populations, East and Southeast 
Asian populations such as the Vietnamese had 
the highest frequency (14.6 % (Veiga et al., 
2009)) compared with the Chinese (Liu et al., 
2011; Nurfadhlina et al., 2006; Oscarson et 
al., 1999b; Schoedel et al., 2004), Korean 
(Djordjevic et al., 2013; Kwon et al., 2001; 
Nakajima et al., 2006; Yoshida et al., 2002) 
and Malaysian (Nurfadhlina et al., 2006) pop-
ulations with a frequency less than 1.5 %. 
However, this allele is not found in the Japa-
nese (Nakajima et al., 2001, 2006; Schoedel 
et al., 2004; Yoshida et al., 2002); South 
Asians such as Indians show a frequency of 
less than 1 % (Krishnakumar et al., 2012; 
Nurfadhlina et al., 2006). Canadian popula-
tions such as the natives (0.5 % (Schoedel et 
al., 2004)) and Caucasians (0.1 % (Schoedel 
et al., 2004)) showed the minimum frequency. 
However, this allele was not found in the Af-
rican, Caucasian, Middle East and American 
mestizo populations (Aklillu et al., 2014; 
Djordjevic et al., 2013, 2010; Gyamfi et al., 
2005; Huang et al., 2005; Malaiyandi et al., 
2006a; Nakajima et al., 2006; Oscarson et al., 
1999b; Rossini et al., 2006). 
CYP2A6*6 has been found only in a Jap-
anese population study at a low frequency 
(0.4 % (Kitagawa et al., 2001)). It not has 
been found in African (Gyamfi et al., 2005; 
Nakajima et al., 2006), Caucasian 
(Malaiyandi et al., 2006a; Nakajima et al., 
2006), Asian (Nakajima et al., 2006; Yoshida 
et al., 2002) or Canadian native populations 
(Schoedel et al., 2004). 
CYP2A6*7 has a higher frequency in East 
and Southeast Asian populations such as Jap-
anese (6.3-13 %) (Fujieda et al., 2004; 
Fukami et al., 2005a; Minematsu et al., 2006; 
Mwenifumbo et al., 2005; Nakajima et al., 
2006; Schoedel et al., 2004; Xu et al., 2002; 
Yoshida et al., 2002), Chinese (2.2-13.8 % 
(Liu et al., 2011; Mwenifumbo et al., 2005; 
Nurfadhlina et al., 2006; Schoedel et al., 
2004; Xu et al., 2002; Yuan et al., 2016)), Ko-
rean (3.6-11.1 % (Djordjevic et al., 2013; 
Fukami et al., 2005a; Mwenifumbo et al., 
2005; Nakajima et al., 2006; Yoshida et al., 
2002)), Taiwanese (10 % (Mwenifumbo et 
al., 2005)), Thai (5-6.4 % (Mahavorasirikul et 
al., 2009; Peamkrasatam et al., 2006)) and 
Malaysian (4.3 % (Nurfadhlina et al., 2006; 
Yusof and Gan, 2009)) populations. It has 
also been reported in a lower frequency in 
Caucasian (≤0.3 % (Fukami, et al., 2005a; 
Malaiyandi et al., 2006a; Mwenifumbo et al., 
2005; Nakajima et al., 2006; Schoedel et al., 
2004; Xu et al., 2002)) and Māori natives 
from New Zealand (1 % (Lea et al., 2008)). 
On the other hand, in Indian, African, Cana-
dian native and Alaskan Yupik populations, 
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this allele is not found (Binnington et al., 
2012; Fukami et al., 2005a; Gyamfi et al., 
2005; Mwenifumbo et al., 2005; Nakajima et 
al., 2006; Nurfadhlina et al., 2006; Schoedel 
et al., 2004). 
CYP2A6*8 has a specific frequency in 
Asian populations such as Malaysian (4.2-
5 % (Nurfadhlina et al., 2006; Yusof and Gan, 
2009), Chinese (≤3.6 % (Nurfadhlina et al., 
2006; Schoedel et al., 2004; Xu et al., 2002)), 
Japanese and Korean (≤2.2 % (Djordjevic et 
al., 2013; Mwenifumbo et al., 2005; Nakajima 
et al., 2006; Schoedel et al., 2004; Xu et al., 
2002; Yoshida et al., 2002)), Indian (0.9 % 
(Nurfadhlina et al., 2006)), Thai (≤0.5 % 
(Mahavorasirikul et al., 2009; Peamkrasatam 
et al., 2006)) and is the lowest in Taiwanese 
(0.2 % (Mwenifumbo et al., 2005)). However, 
it has not been found in African, Caucasian, 
Canadian natives and Alaskan Yupik popula-
tions (Binnington et al., 2012; Gyamfi et al., 
2005; Malaiyandi et al., 2006a; Mwenifumbo 
et al., 2005; Nakajima et al., 2006; Schoedel 
et al., 2004; Xu et al., 2002). 
CYP2A6*9 is the most widely studied de-
creased function allele. Asian populations 
show the highest frequency: East Asian pop-
ulations (Chinese, Korean and Japanese) had 
a frequency between 15-20 % (Benowitz et 
al., 2006; Djordjevic et al., 2013; Fujieda et 
al., 2004; Liu et al., 2011; Minematsu et al., 
2006; Nakajima et al., 2006; Pitarque et al., 
2001; Schoedel et al., 2004; Yoshida et al., 
2003; Yuan et al., 2016), followed by South 
Asian population as Thai (12.1-20.4 % 
(Mahavorasirikul et al., 2009; Peamkrasatam 
et al., 2006)) and Malaysian (10.4 % (Yusof 
and Gan, 2009)); Middle East populations as 
Turkish (6.9-7.2 % (Pitarque et al., 2001; von 
Richter et al., 2004)), Iranian (12.4 % 
(Emamghoreishi et al., 2008)) and some eth-
nic groups among them (Sepehr et al., 2004) 
such as Turkomans (14 %), Turks (5 %) and 
Zoroastrian Persian (4 %) showed a high fre-
quency. Mediterranean European (Spanish 
(Soriano et al., 2011) and Serbian (Djordjevic 
et al., 2010)), North European (Swedish 
(Djordjevic et al., 2013; Pitarque et al., 2001)) 
and Central European (Hungarian (Fiatal et 
al., 2016)) populations show a frequency 
range of 5-8 %, which is the same as Cauca-
sian (Audrain-McGovern et al., 2007; 
Benowitz et al., 2006; Haberl et al., 2005; 
Malaiyandi et al., 2006a, b; Nakajima et al., 
2006, 2004; Schoedel et al., 2004) and North 
American Caucasian populations (Bloom et 
al., 2011; O’Loughlin et al., 2004). A differ-
ent pattern occurs in African populations; Af-
rican and African American show a frequency 
of 7-10 % (Ho et al., 2009; Mwenifumbo et 
al., 2008; Nakajima et al., 2006, 2004; 
Schoedel et al., 2004), but in populations with 
a more conserved African component as Gha-
naian (5.7 % (Gyamfi et al., 2005)) and Ethi-
opian (2.8 % (Aklillu et al., 2014)) the fre-
quency is lower. Amerindian populations 
such as Canadian natives (15.5 % (Schoedel 
et al., 2004)) and Alaskan Yupik (8.9 % 
(Binnington et al., 2012)) had a heterogene-
ous frequency, which was the same as Amer-
ican mestizo populations such as Brazilian 
(5.7 % (Vasconcelos et al., 2005)), Ecuado-
rian (10.3 % (Soriano et al., 2011)), Mexican 
(16.4 % (Svyryd et al., 2015)) and other His-
panics (7.1 % (Benowitz et al., 2006)). The 
only population in Oceania to report this al-
lele is the native population Māori from New 
Zealand with 19 % (Lea et al., 2008). 
CYP2A6*10 has been reported to be 
higher among Asian populations as Japanese 
(1-4.3 %) (Fujieda et al., 2004; Mwenifumbo 
et al., 2005; Nakajima et al., 2006; Schoedel 
et al., 2004; Xu et al., 2002; Yoshida et al., 
2002), Chinese (0.4-4.3 % (Liu et al., 2011; 
Mwenifumbo et al., 2005; Nurfadhlina et al., 
2006; Schoedel et al., 2004; Xu et al., 2002)), 
Korean (0.5-4.2 %) (Djordjevic et al., 2013; 
Mwenifumbo et al., 2005; Nakajima et al., 
2006; Yoshida et al., 2002), Malaysian 
(4.3 %) (Nurfadhlina et al., 2006), Taiwanese 
(4.1 %) (Mwenifumbo et al., 2005) and Thai 
(1.6-2.4 %) (Mahavorasirikul et al., 2009; 
Peamkrasatam et al., 2006); and the Alaskan 
Yupik population with 1.9 % (Binnington et 
al., 2012). However, Indian (Nurfadhlina et 
al., 2006), Caucasian (Malaiyandi et al., 
2006a; Mwenifumbo et al., 2005; Nakajima et 
al., 2006; Schoedel et al., 2004; Xu et al., 
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2002), African (Gyamfi et al., 2005; 
Mwenifumbo et al., 2005; Nakajima et al., 
2006; Schoedel et al., 2004) and even Cana-
dian native populations (Schoedel et al., 
2004) do not show any frequency. 
CYP2A6*11 is not well-reported. How-
ever, it has been reported in a minimum fre-
quency in Japanese and Korean populations at 
0.5-0.7 % (Fujieda et al., 2004; Nakajima et 
al., 2006). The few analyzed African and Cau-
casian populations did not report this allele. 
CYP2A6*12 has been reported at the high-
est frequency among the studied populations 
in Hispanics (3.5-4.7 % (Benowitz et al., 
2006; Koontz et al., 2009)) and Mexican 
(3.5 % (Borrego-Soto et al., 2015)) popula-
tion. The frequency decreases in Caucasians 
(≤3 % (Audrain-McGovern et al., 2007; 
Benowitz et al., 2006; Haberl et al., 2005; 
Koontz et al., 2009; Malaiyandi et al., 2006a, 
b; Nakajima et al., 2006; Schoedel et al., 
2004)), Spanish (2.2 % (Oscarson et al., 
2002)) and Canadian populations (1.1 % 
(O’Loughlin et al., 2004)). Then, in Asians, 
similar to in Middle East populations such as 
Iranians, it is reported in 1.3 % 
(Emamghoreishi et al., 2008), but in East Asia 
only Japanese had a minimum frequency 
(0.8 % (Nakajima et al., 2006; Schoedel et al., 
2004)) while Chinese and Korean populations 
(Benowitz et al., 2006; Koontz et al., 2009; 
Nakajima et al., 2006; Oscarson et al., 2002; 
Schoedel et al., 2004) did not report any fre-
quency of the allele. Lastly, Amerindian pop-
ulations such as Canadian natives and Alas-
kan Yupik reported a very low frequency 
(0.4-0.5 % (Binnington et al., 2012; Schoedel 
et al., 2004)). In African populations, some 
studies show a low frequency (0.4 %) (Ho et 
al., 2009; Schoedel et al., 2004) and others do 
not show any frequency (Benowitz et al., 
2006; Koontz et al., 2009; Mwenifumbo et al., 
2008; Nakajima et al., 2006). 
CYP2A6*13 has been reported in Japa-
nese (1.1-1.5 % (Kiyotani et al., 2002; 
Nakajima et al., 2006)) and Koreans (0.2 % 
(Nakajima et al., 2006)). It was not found in 
Caucasians and Africans (Kiyotani et al., 
2002; Nakajima et al., 2006). 
CYP2A6*14 has a higher frequency in 
Caucasian (3.5-5.2 % (Haberl et al., 2005; 
Kiyotani et al., 2002; Nakajima et al., 2006)) 
than in African (0.9-1.4 % (Mwenifumbo et 
al., 2008; Nakajima et al., 2006)), but was not 
reported in Asians (Japanese and Korean) 
(Kiyotani et al., 2002; Nakajima et al., 2006). 
CYP2A6*15 has been reported at a mini-
mum frequency in Japanese (1.5-2.2 % 
(Kiyotani et al., 2002; Nakajima et al., 2006)) 
and Korean (1.2 % (Nakajima et al., 2006)), 
but not in Caucasian and African populations 
(Kiyotani et al., 2002; Mwenifumbo et al., 
2008; Nakajima et al., 2006). 
CYP2A6*16 has been reported in Cauca-
sian (0.3-3.6 %) and African (0-1.7 %) popu-
lations (Kiyotani et al., 2002; Mwenifumbo et 
al., 2008; Nakajima et al., 2006), but not in 
Japanese or Korean populations (Kiyotani et 
al., 2002; Nakajima et al., 2006). 
CYP2A6*17 has a frequency of approxi-
mately 7.3-10.5 % in African populations 
(Fukami et al., 2004; Ho et al., 2009; 
Mwenifumbo et al., 2008; Nakajima et al., 
2006), but not in Caucasian, Korean, Japanese 
or Alaskan Yupik (Binnington et al., 2012; 
Fukami et al., 2004; Nakajima et al., 2006) 
populations. 
CYP2A6*18 has a higher frequency range 
in Caucasian (0.3-2.2 % (Fukami et al., 
2005a; Haberl et al., 2005; Nakajima et al., 
2006)) than in Korean (0.3-0.5 % (Fukami et 
al., 2005a; Nakajima et al., 2006)), but has not 
been found in Japanese and African popula-
tions (Fukami et al., 2005a; Nakajima et al., 
2006). 
CYP2A6*19 has been reported in a low 
frequency in Korean (1-1.4 % (Djordjevic et 
al., 2013; Fukami et al., 2005a; Nakajima et 
al., 2006)) and Japanese (0.5 % ), but not in 
Caucasian nor African (Fukami et al., 2005a; 
Nakajima et al., 2006) populations. 
CYP2A6*20 is present in African popula-
tion at a frequency range between 1-1.7 % 
(Fukami et al., 2005b; Ho et al., 2009; 
Mwenifumbo et al., 2008; Nakajima et al., 
2006). This allele was not reported in Cauca-
sian, Japanese and Korean populations 
(Fukami et al., 2005b; Nakajima et al., 2006). 
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CYP2A6*21 has a higher frequency in 
Caucasian (0.5-2.3 %) (Al Koudsi et al., 
2006; Haberl et al., 2005; Nakajima et al., 
2006) than in African populations (0.6-0.7 % 
(Mwenifumbo et al., 2008; Nakajima et al., 
2006)). It has not been reported in Japanese or 
Korean (Nakajima et al., 2006) populations. 
CYP2A6*22 has been reported at fre-
quency less than 0.3 % (Haberl et al., 2005; 
Nakajima et al., 2006) in Caucasian popula-
tions, but not in Japanese or Korean 
(Nakajima et al., 2006) populations. 
CYP2A6*23 has a frequency range among 
1-2 % (Ho et al., 2009 , 2008; Mwenifumbo 
et al., 2008) in African populations, but was 
not reported in Caucasian, Japanese or Chi-
nese populations (Ho et al., 2008). 
CYP2A6*24 has a frequency range among 
0.7-1.3 % in African populations (Al Koudsi 
et al., 2010; Ho et al., 2009; Mwenifumbo et 
al., 2008), but it has not been found in Cauca-
sian, Chinese, Japanese and Taiwanese (Al 
Koudsi et al., 2010) populations. 
CYP2A6*25-*28 has only been reported 
in African populations, while CYP2A6*26-
*27 has a frequency range of 0.7-0.9 % (Ho et 
al., 2009; Mwenifumbo et al., 2008) and 
CYP2A6*28 from 0.9-2.4 % (Ho et al., 2009; 
Mwenifumbo et al., 2008). 
CYP2A6*31, *34 and *38 have not been 
studied in any population. 
CYP2A6*35 has been reported at a fre-
quency between 2.5-2.9 % (Al Koudsi et al., 
2010; Ho et al., 2009) in African populations 
living in North American countries. In East 
Asian populations, such as Chinese, Japanese 
and Taiwanese, it has been found at a fre-
quency of 0.5-0.8 % (Al Koudsi et al., 2010), 
but it has not been found in Caucasian or 
Alaska Yupik (Al Koudsi et al., 2010; 
Binnington et al., 2012) populations. 
CYP2A6*36 and *37 has been reported in 
Taiwanese populations at a frequency of 
0.3 %, but not in African, Caucasian, Chinese 
nor Japanese (Al Koudsi et al., 2010) popula-
tions. 
CYP2A6*39 (0.6 %), *40 (0.2 %), *41 
(1.2 %), *42 (0.2 %), *43 (0.2 %), *44 
(0.2 %) and *45 (0.6 %) have only been re-
ported in the African population (Piliguian et 
al., 2014). 
The gene duplication, CYP2A6*1X2, has 
been found at higher frequency in Asian pop-
ulations as Asian (7.1 % (Benowitz et al., 
2006)), Indian (3.5 % (Nurfadhlina et al., 
2006)), Chinese (0.4-1.5 %) (Nurfadhlina et 
al., 2006; Schoedel et al., 2004; Xu et al., 
2002), Korean (≤0.2 %) (Fukami et al., 2007; 
Nakajima et al., 2006) and Malaysian (0.4 %) 
(Nurfadhlina et al., 2006); the Hispanic popu-
lation (3.5 %) (Benowitz et al., 2006) has a 
higher frequency than the Ecuadorian popula-
tion (0.5 %) (Soriano et al., 2011); Caucasian 
populations have a frequency less than 2 % as 
in some Caucasian groups (≤1.7 %) 
(Benowitz et al., 2006; Fukami et al., 2007; 
Nakajima et al., 2006; Rao et al., 2000; 
Schoedel et al., 2004; Xu et al., 2002), Span-
ish (1.2 %) (Soriano et al., 2011), Swedish 
(0.8 %) (Djordjevic et al., 2013), Serbian 
(0.4 %) (Djordjevic et al., 2010), North 
American (0.3 %) (Bloom et al., 2011) and 
Canadian (0.2 %) (O’Loughlin et al., 2004). 
In African populations, such African Ameri-
can (1.7 % (Fukami et al., 2007)) and Ethio-
pian (0.3 % (Aklillu et al., 2014)), this allele 
was present, but was not found in other Afri-
can groups, Canadian natives or Alaskan Yu-
pik (Binnington et al., 2012; Nakajima et al., 
2006; Schoedel et al., 2004). 
Most studies address the majority of a 
country’s population as a general population. 
However, a few studies focus on more spe-
cific population classifications as ethnic and 
regional groups. In the Asian population, it 
was studied among Tottori, Shimane, Ehime 
and Fukuoka people of the respective districts 
of Yonago, Izumo, Matsuyama and Kurume 
located in Japan (Takeshita et al., 2006). In 
China, it has been compared in the prevailing 
Han Chinese group and the Uighur, Bouyei 
and Tibetan ethnic groups (Pang et al., 2015). 
In the South of India, the frequencies of the 
people from Andhra Pradesh, Karnataka, Ker-
ala and Tamil Nadu regions (Krishnakumar et 
al., 2012) were compared. In Iran, some eth-
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nic groups such as Turkomans from the Go-
lestan Province, Turks from the Ardabil Prov-
ince and Zoroastrian Persians from Tehran 
(Sepehr et al., 2004) were studied. In Russia, 
the Tatar ethnic group was reported (Korytina 
et al., 2014). In African populations, the eth-
nic group Ovambo from Namibia was re-
ported (Takeshita et al., 2006); and some eth-
nic groups such as Akan, Guan, Ewe, Ga, 
Nzima and Dargarti, but there were a few par-
ticipants that were added in a single Ghanaian 
population (Gyamfi et al., 2005). In Oceania, 
the Māori ethnic group from New Zealand is 
the only population reported across the conti-
nent (Lea et al., 2008). In the American con-
tinent, the ethnic groups such as Yupik from 
Alaska and Canadian natives have been re-
ported (Binnington et al., 2012; Nowak et al., 
1998; Schoedel et al., 2004). 
 
CONCLUSIONS AND PERSPECTIVES 
The enzyme responsible for metabolizing 
nicotine is mostly encoded by the CYP2A6 
gene, which is highly polymorphic. This var-
iability is due to changes in DNA, which have 
generated different responses to nicotine and 
are reflected in the individual smoking behav-
iors along with other factors. It has been re-
ported that this variability has been generated 
and distributed over a long time in different 
human populations, showing well defined 
ethnic patterns. Although association studies 
between carriers of certain variants and differ-
ent smoking behaviors have been numerous 
with plausible results, population studies re-
porting frequencies of these variants are few. 
General population studies exhibit most relia-
ble information than association studies with 
a variable frequency, because the population 
requirements are usually more specific, creat-
ing a population bias. However, it would be 
advisable to address this type of methodology 
in higher risk populations of smoking and 
those where policies to control smoking are 
less efficient, and where more smoking-re-
lated diseases are reported in the population. 
Additionally, the population must be charac-
terized by more specific requirements, such as 
including the ancestry informative markers 
and avoiding "self-reporting" as the unique 
classification criteria. While there is a Human 
CYP-Allele Nomenclature Database in which 
the genetic findings of CYP2A6 are unified, it 
is necessary to supplement it with updated 
data as per the population distribution. All of 
this could contribute to a personalized system 
that could detect, prevent and treat popula-
tions at risk of smoking, and in consequence, 
avoid tobacco consumption related diseases.  
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